Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | -5.62% | -11.65% | +33.52% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 20.07M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -24M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.18
x | P/E ratio 2025 * |
-1.65
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.13% |
1 day | -5.62% | ||
1 week | -11.65% | ||
Current month | +4.91% | ||
1 month | +1.29% | ||
3 months | +36.12% | ||
6 months | +1.73% | ||
Current year | +33.52% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 21-02-23 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 21-08-02 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 21-08-02 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 21-08-02 |
Director/Board Member | 61 | 23-01-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.35 | -5.62% | 49,609 |
24-04-23 | 2.49 | +2.05% | 7,360 |
24-04-22 | 2.44 | +3.39% | 4,186 |
24-04-19 | 2.36 | -6.35% | 10,645 |
24-04-18 | 2.52 | -5.26% | 27,005 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.52% | 21.26M | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- INDP Stock